F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBankÂ®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.
Current Team (10)Update
Funding Rounds (2) - $41.8MUpdate
Board Members and Advisors (3)Update
Advent Venture Partners is one of Europe's most successful growth and venture capital...
Experienced European Private Investment
European early stage venture capital firm
Corporate venture capital
Biotech Investment group
PO Box 1, Lankro Way, Eccles
Manchester, M30 0BH